/PRNewswire/ Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to.
Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
News provided by
Share this article
Share this article
HARRISON, N.Y., May 18, 2021 /PRNewswire/ Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it was awarded a Small Business Innovative Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to investigate the inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide. The grant will provide funds over two years to support the discovery and development of peptide therapeutics against coronaviruses, including SARS-CoV-2 (COVID-19).
Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Abstract Control Number: 3578
Session Type: E-Poster Session
Session Title: Biological Therapeutic Agents
Permanent Abstract Number: 959
Abstract Control Number: 3677
Session Type: E-Poster Session
Session Title: Biological Therapeutic Agents
Permanent Abstract Number: 964
About ST101
ST101 is a peptide inhibitor of C/EBPβ, which is a transcription factor overexpressed in many cancers that regulate cellular differentiation and promote tumor survival and proliferation. ST101 significantly decreases the expression of C/EBPβ target genes/proteins involved in cell survival, proliferation and differentiation including BCL-2, MCL-1, BIRC5/survivin, cyclins and ID family of proteins. ST101 has been demonstrated to induce selective cancer cell cytotoxicity across a variety of tumor types, including but not limited to breast cancer, melanoma, prostate cancer, GBM, lung cancer, and AML. C/EBPβ is expressed and active in cancer cells but not active in normal cells (post-dif
(2)
HARRISON, NY / ACCESSWIRE / March 4, 2021 / Sapience Therapeutics, Inc., a clinical stage biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, today announced that Dr. Barry Kappel, President and Chief Executive Officer, will present an overview of the company and provide an update on the ST101 clinical trial at the upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley. During the 20-minute presentation, participants will be able to submit questions electronically with answers provided at the discretion of the company on an individual basis afterwards. Details are as follows: